NewLink Genetics Corp (NASDAQ:NLNK) has today made an announcement regarding its entry into a clinical partnership agreement with AstraZeneca plc (ADR) (NYSE:AZN). The two business giants will be seeking to evaluate the combination of durvalumab with indoximod along with the standard solution of chemotherapy for persons struggling with metastatic pancreatic cancer. The primary goal for the company’s […]
NYSE:AZN
Pfizer Inc. (NYSE:PFE) Wins A $40 Million Bid By BIND Therapeutics Inc (NASDAQ:BIND)
Pfizer Inc. (NYSE:PFE) was the winner of a $40 million bid by BIND Therapeutics Inc (NASDAQ:BIND). PFE succeeded at a Section 363 auction initiated by the Cambridge, Massachusetts-based biotechnology company which is selling off its assets. Among other two unidentified companies that had joined the auction Pfizer’s bid was selected as the highest and best. […]
Flagship Ventures Gets In Deal With AstraZeneca plc (ADR) (NYSE:AZN), Nestle and Bayer
Flagship Ventures has recruited three of big name corporate sponsors to use their expertise to its next class of seedlings. The move will expand Flagship Ventures’ focus beyond its traditional drug development. Flagship has separate partnership with AstraZeneca plc (ADR) (NYSE:AZN), Nestle and Bayer. The partnership is expected to upgrade Flagships faculty at Venture Labs. […]
Pfizer Inc. (NYSE:PFE) – Testing Support Band In $33.50-$34.00
Pfizer Inc. (NYSE:PFE) spent the last trading session almost flat as it ended the day with a minor loss of 0.55% but the next trading may take a different color after the announcement of the last quarterly results. The company has beat the street estimates overcoming the patent expirations and Dollar strength but the guidance […]
Celgene Corporation (NASDAQ:CELG) to buy Cancer research Company Quanticel Pharmaceuticals
Celgene Corporation (NASDAQ:CELG) is buying up Quanticel Pharmaceuticals for a deal worth $485 million. The deal comes after Clegene teamed up with Versant Ventures to help Quanticel get off the ground Quanticel is a cancer focused biotech and has a drug recover engine that uses single cell genomic analysis to decode cancer cells and highlight […]
Acquisition of BP May Be Halted On Public PolicyGrounds
David Cameron has given informal private assurance to BP that any move to take over the company will be resisted. It is, however, unclear what the government would do if faced with a takeover. The Government could erect a few obstacles in hurry and hope for the bidder to go away as it did in […]
Juno Therapeutics Inc (NASDAQ:JUNO) and AstraZeneca plc (ADR) (NYSE:AZN) Pair Up for new Cancer Therapy
Juno Therapeutics Inc (NASDAQ:JUNO) and AstraZeneca plc (ADR) (NYSE:AZN) are collaborating to test their respective cancer therapies in tandem. The collaboration will combine new-fangled therapies that will use the immune system to combat tumours. Under the deal, the duo will jointly fund a Phase I study that combines Juno’s CAR-T therapy and antibodies developed by […]
AstraZeneca plc (ADR) (NYSE:AZN) Innovation Lynparza Shows Promising Prostate And Ovarian Cancer Trials
AstraZeneca plc (ADR) (NYSE:AZN) has finally unveiled its wonder-drug Lynparza or Olaparib that works in curing men from the vagaries of prostate cancer. The company has conducted several tests and clinical trials, following which it has revealed its drug that can cure ovarian or prostate cancer in females and males respectively. Justice To Prior Pfizer-Takeover […]
FDA Promises Speedy Review For AstraZeneca plc (ADR) (NYSE:AZN) Lung Cancer Drug On Positive Phase II Study
AstraZeneca plc (ADR) (NYSE:AZN) promise of delivering annual revenues of $45 billion by 2023 received a major boost after its lung cancer drug impressed in a phase II study against Clovis. The drug was found to extend the survival rate of patients by more than a year an indication that it can be used as […]
AutoZone, Inc. (NYSE:AZN): S&P Capital IQ Analyst, Efraim Levy, Believes Lower-End Consumers Remain Cautious
Boston, MA 09/23/2014 (wallstreetpr) – Investment advisor, S& Capital IQ thinks that the chain of retailer and distributor of automotive replacement accessories and parts, AutoZone, Inc. (NYSE:AZN), has experienced cautious approach among its lower-end consumers in the recent quarter ended in August. The comments come on the heels of AutoZone reporting its fourth quarter, as […]
Major Movers: Spectra Energy (SE), Eli Lilly and Co (LLY), Sino-Global Shipping America (SINO), Digital Power (DPW)
Denver, CO, 09/16/2014, (Avauncer.com) – Spectra Energy Corp. (NYSE:SE), Spectra Energy Partners (NYSE:SEP) and Northeast Utilities (NYSE:NU) announced the details of their natural gas project known as Access Northeast. The project aims to meet the increasing demand for natural gas in New England. The companies said the project will guarantee daily natural gas supplies to […]
AstraZeneca plc (ADR) (NYSE:AZN) To Enter Into Partnership With Eli Lilly and Co (NYSE:LLY) On Alzheimer’s Drug
Boston, MA 09/16/2014 (wallstreetpr) – According to reports, AstraZeneca plc (ADR) (NYSE:AZN) has decided to enter into a partnership with Eli Lilly and Co (NYSE:LLY) in order to ensure a smooth development of Alzheimer’s drug. The deal will cost around $500 million to AZN. As per the information, British Group had decided to come up […]
Will Pfizer Inc. (NYSE:PFE) Make An Attempt Acquire Astrazeneca Plc (ADR) (NYSE:AZN)?
Boston, MA 09/04/2014 (wallstreetpr) – Even though the much-talked about merger deal between Pfizer Inc. (NYSE:PFE) and AstraZeneca plc (ADR) (NYSE:AZN) died down, but according to the U.K. acquisition rules, the former still has chances of bringing the deal on the table. Even though the deal cancellation was a relief for British Pharma, but as per […]
Pfizer Inc. (NYSE:PFE) Can Raise Its Bid For AstraZeneca plc (ADR) (NYSE:AZN)
Boston, MA 08/25/2014 (wallstreetpr) – It seems Pfizer Inc. (NYSE:PFE) is adamant for an overseas takeover to get the tax inversion benefits and expand its product portfolio. It can place a renew bid for AstraZeneca plc (ADR) (NYSE:AZN), on November 26, 2014. But if AstraZeneca wants, it can invite Pfizer for further discussion after August […]
Pfizer Inc. (NYSE:PFE)’s Multipronged Approach To Tax Issue, Whichever Comes First Is Good
Boston, MA 08/18/2014 (wallstreetpr) – Pfizer Inc. (NYSE:PFE), a $182 billion market capped company whose shares are down 6.5% this year, does not hide its intentions to renounce its U.S. corporate citizenship to pursue tax havens in Europe. Shares of the company declined 0.31% to $28.64 on Friday, marking another day of decline. Talking about […]
